The importance of imaging and physiology measurements in assessing the delivery of peripherally targeted aerosolized drugs

Therapeutic Delivery

Volumn 3, Issue 11, 2012, Pages 1329-1345

  Biddiscombe, Martyn F ^a   Usmani, Omar S ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOLIZED DRUG; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GALLIUM 68; NITRIC OXIDE; NITROGEN 13; OXYGEN 15; PENTETATE IRON TECHNETIUM TC 99M; RESPIRATORY TRACT AGENT; TECHNETIUM 99M; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

AEROSOL; ASTHMA; CONTRAST ENHANCEMENT; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SCREENING; EXPIRATORY FLOW RATE; GAMMA SCINTIGRAPHY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGING; ISOTOPE TRACING; LOW DRUG DOSE; LUNG CLEARANCE; LUNG FUNCTION TEST; LUNG IMAGING; NITROGEN WASHOUT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OSCILLOMETRY; PHARMACOSCINTIGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DECAY; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMALL AIRWAY DISEASE; SPIROMETRY; TARGET ORGAN; THREE DIMENSIONAL IMAGING;

EID: 84870159759     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.113     Document Type: Review

References (120)

1. Lenzer J. Inhaled insulin is approved in Europe and United States. BMJ. 332(7537), 321 (2006).
2. Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir. Care 5 0 (9), 1161-1176 (2005).
3. Carroll N, Elliot J, Morton A, James A. The structure of large and small airways in nonfatal and fatal asthma. Am. Rev. Respir. Dis. 147(2), 405-410 (1993). (Pubitemid 23044915)
4. Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural ana lysis of peripheral airways and arteries in sudden fatal asthma. Am. Rev. Respir. Dis. 143(1), 138-143 (1991).
5. Mead J. The lung's 'quiet zone '. N. Engl. J. Med. 282, 1318-1319 (1970).
6. Verbanck S, Schuermans D, Paiva M, Vincken W. The functional beneft of anti-infammatory aerosols in the lung periphery. J. Allergy Clin. Immunol. 118(2), 340-346 (2006). (Pubitemid 44142721)
7. Cohen J, Douma WR, ten Hacken NHT, Vonk JM, Oudkerk M, Postma DS. Ciclesonide improves measures of small airway involvement in asthma. Eur. Respir. J. 31(6), 1213-1220 (2008).
8. Cohen J, Douma WR, Van Ooijen PM et al. Localization and quantifcation of regional and segmental air trapping in asthma. J. Comput. Assist Tomogr. 32(4), 562-569 (2008).
9. Scheuch G, Bennett W, Borgström L et al. Deposition, imaging, and clearance: what remains to be done? J. Aerosol Med. Pulm. Drug. Deliv. 23 (2), S39-S57 (2010).
10. King GG. Current and emerging imaging in relation to drug discovery in airways disease. Pulm. Pharmacol Therap. 24(5), 497-504 (2011).
11. Newman S, Fleming J. Challenges in assessing regional distribution of inhaled drug in the human lungs. Expert Opin. Drug Deliv. 8(7), 841-855 (2011).
12. Conway J. Lung imaging-two dimensional gamma scintigraphy, SPECT, CT and PET. Adv. Drug Deliver. Rev. 64(4), 357-368. (2012).
13. Leach CL, Kuehl PJ, Chand R et al. Characterization of respiratory deposition of futicasone-salmeterol hydrofuoroalkane-134a and hydrofuoroalkane-134a beclomethasone in asthmatic patients. Ann. Allergy Asthma Immunol. 108(3), 195-200 (2012).
14. Gelfand EW, Kraft M. The importance and features of the distal airways in children and adults. J. Allergy Clin. Immunol. 124(6), S84-S87 (2009).
15. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J. Allergy Clin. Immunol. 124(6), S88-S93 (2009).
16. Eberl S, Chan H-K, Daviskas E. SPECT imaging for radioaerosol deposition and clearance studies. J. Aerosol Med. 19(1), 8-20 (2006).
17. ICRP Publication 80: Radiation dose to patients from radiopharmaceuticals. J Valentin (Ed.). Elsevier Science, Oxford, UK (1998).
18. Newman SP, Pitcairn GR, Hirst PH. A brief history of gamma scintigraphy. J. Aerosol Med. 14(2), 139-145 (2001). (Pubitemid 32744346)
19. Pauwels R, Newman S, Borgström L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur. Respir. J. 10, 2127-2138 (1997). (Pubitemid 27406455)
20. Köhler D, Fleischer W, Matthys H. New method for easy labelling of beta-2-agonists in the metered dose inhaler with technetium-99m. Respiration 53, 65-73 (1988).
21. Biddiscombe MF, Melchor R, Mak VHF et al. The lung deposition of salbutamol, directly labelled with technetium-99m, delivered by pressurised metered dose and dry powder inhalers. Int. J. Pharm. 91, 111-121 (1993). (Pubitemid 23159814)
22. Möller W, Meyer G, Kreyling WG. Advances in lung imaging techniques for the treatment of respiratory disease. DDSTR 5, 87-92 (2008).
23. Bondesson E, Bengtsson T, Borgström L et al. Dose delivery late in the breath can increase dry powder aerosol penetration into the lungs. J. Aerosol Med. 18(1), 23-33 (2005). (Pubitemid 40349944)
24. Daviskas E, Anderson SD, Eberl S, Young LH. Effect of increasing doses of mannitol on mucus clearance in patients with bronchiectasis. Eur. Respir. J. 31, 765-772 (2008).
25. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am. J. Respir. Crit. Care Med. 172(12), 1497-1504 (2005). (Pubitemid 43076536)
26. Biddiscombe MF, Meah SN, Underwood SR, Usmani OS. Comparing lung regions of interest in gamma scintigraphy for assessing inhaled therapeutic aerosol deposition. J. Aerosol Med. Pulm. Drug Deliv. 24(3), 1-9 (2011).
27. Fleming JS, Conway JH, Majoral C et al. The use of combined single photon emission computed tomography and x-ray computed tomography to assess the fate of inhaled aerosol. J. Aerosol Med. Pul. Drug Del. 24(1), 49-60 (2011).
28. Leach CL, Bethke TD, Boudreau RJ et al. Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: A nonrandomized study in healthy volunteers. J. Aerosol Med. 19(2), 117-127 (2006).
29. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir. Med. 100(3), 375-384 (2006). (Pubitemid 43239871)
30. Eberl S, Chan H-K, Daviskas E. SPECT imaging for radioaerosol deposition and clearance studies. J. Aerosol Med. 19, 8-20 (2006).
31. Glover W, Chan H-K, Eberl S, Daviskas E, Verschuer J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int. J. Pharm. 349, 314-322 (2008). (Pubitemid 350299704)
32. Fleming JS, Sauret V, Conway JH, Martonen TB. Validation of the conceptual anatomical model of the lung airway. J. Aerosol Med. 17(3), 260-269 (2004). (Pubitemid 39299327)
33. Perring S, Summers Q, Fleming JS et al. A new method of quantifcation of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. Br. J. Radiol. 67, 46-53 (1994). (Pubitemid 24026446)
34. Martonen T, Fleming J, Schroeter J, Conway J, Hwang D. In silico modeling of asthma. Adv. Drug Deliv. Rev. 55(7), 829-849 (2003). (Pubitemid 36776796)
35. Martonen TB, Schroeter JD, Fleming JS. 3D in-silico modelling of the human respiratory system for inhaled drug delivery and imaging analysis. J. Pharm. Sci. 96, 603-617 (2007). (Pubitemid 46466082)
36. Kotzerke J, Andreeff M, Wunderlich G. PET aerosol lung scintigraphy using Galligas. Eur. J. Nucl. Med. Mol. Imaging 3 7(1), 175-177 (2010).
37. Hofman MS, Beauregard J-M, Barber TW, Neels OC, Eu P, Hicks RJ. 68Ga PET/CT ventilation-perfusion imaging for pulmonary embolism: A pilot study with comparison to conventional scintigraphy. J. Nucl. Med. 52, 1513-1519 (2011).
38. Dolovich MB. 18F-Fluorodeoxyglucose positron emission tomographic imaging of pulmonary functions, pathology, and drug delivery. Proc. Am. Thorac. Soc. 6, 477-485 (2009).
39. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and infammation. Semin. Nucl. Med. 32(2), 47-59 (2002). (Pubitemid 34112942)
40. Dolovich M, Labiris R. Imaging drug delivery and drug responses in the lung. Proc. Am. Thorac. Soc. 1, 329-337 (2004).
41. Rahman S, Rhodes CG, Constantinou M et al. Lung Deposition of 18F-futicasone propionate in normal subjects using positron emission tomography. Am. J. Respir. Crit. Care Med. 161, A177 (2000).
42. Visser TJ, Van Waarde A, Doze P et al. Characterisation of beta2-adrenoceptors, using the agonist [11C] formoterol and positron emission tomography. Eur. J. Pharmacol. 361, 35-41 (1998). (Pubitemid 28522156)
43. Dolovich M, Rhem R, Guo H, Labiris NR, Thabane L. Does particle size infuence distribution of inhaled therapy in the presence of airways obstruction: A 3D PET study of the lung in cystic fbrosis. Proc. Am. Thorac. Soc. 2, Abstract A377 (2005).
44. Musch G, Venegas JG. Positron emission tomography imaging of regional pulmonary perfusion and ventilation. Proc. Am. Thorac. Soc. 2, 522-527 (2005). (Pubitemid 43128023)
45. Rhodes CG, Hughes JMB. Pulmonary studies using positron emission tomography. Eur. Respir. J. 8, 1001-1017 (1995).
46. De Wever W, Stroobants S, Coolen J, Verschakelen JA. Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur. Respir. J. 33(1), 201-212 (2009).
47. Pahwa R, Dutt H, Kumar V, Kohli K. Pharmacoscintigraphy: An emerging technique for evaluation of various drug delivery systems. Arch. Appl. Sci. Res. 2(5), 92-105 (2010).
48. Jaafar-maalej C, Elaissari A, Fessi H. Assessment methods of inhaled aerosols: technical aspects and applications. Expert Opin. Drug Deliv. 6(9), 941-959 (2009).
49. Lipworth B. Pharmacokinectics of inhaled drugs. Br. J. Clin. Pharmacol. 42(6), 697-705 (1996).
50. Hirst P, Pitcairn G, Richards J. Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. J. Aerosol Med. 14(2), 155-165 (2001). (Pubitemid 32744348)
51. Jain S, Dani P, Sharma RK. Pharmacoscintigraphy: A blazing trail for the evaluation of new drugs and delivery systems. Crit. Rev. Ther. Drug Carrier Syst. 26(4), 373-426 (2009).
52. Castro M, Fain SB, Hoffman EA, Gierada DS, Erzurum SC, Wenzel S. Lung imaging in asthmatic patients: the picture is clearer. J. Allergy Clin. Immunol. 128, 467-478 (2011).
53. Ueda T, Niimi A, Matsumoto H, Takemura M, Hirai T, Yamaguchi M et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J. Allergy Clin. Immunol. 118, 1019-1025 (2006). (Pubitemid 44666982)
54. Abbott GF, Rosado-de-Christenson ML, Rossi SE, Suster S. Imaging of small airways disease. J. Thorac. Imaging 24, 285-298 (2009).
55. Tashkin DP, de Lange EE. Imaging of the distal airways. J. Allergy Clin. Immunol. 124, S78-S83 (2009).
56. Burgel P-R. The role of small airways in obstructive airway diseases. Eur. Respir. Rev. 2 0 (119), 23-33 (2011).
57. Tschirren J, Hoffman E, McLennan G, Sonka M. Segmentation and quantitative ana lysis of intrathoracic airway trees from computed tomography images. Proc. Am. Thorac. Soc. 2, 484-487 (2005). (Pubitemid 43128019)
58. King GG, Carroll JD, Müller NL et al. Heterogeneity of narrowing in normal and asthmatic airways measured by HRCT. Eur. Respir. J. 24(2), 211-218 (2004). (Pubitemid 39139787)
59. Tunon-de-Lara J, Laurent F, Giraud V et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J. Allergy Clin. Immunol. 119, 583-590 (2007). (Pubitemid 46335813)
60. Cohen J, Douma WR, Van Ooijen PMA et al. Localization and quantifcation of regional and segmental air trapping in asthma. J. Comput. Assist. Tomogr. 32(4), 562-569 (2008).
61. Spaggiari E, Zompatori M, Verduri A et al. Early smoking-induced lung lesions in asymptomatic subjects. Correlations between high resolution dynamic CT and pulmonary function testing. Radiol. Med. 109 (1-2), 27-39 (2005).
62. Bennett M, Havelock T, Conway J, Fleming J. Anatomically derived regional measurements of lung function of aerosol deposition. J. Aerosol Med. Pul. Deliv. 24(3), PD12, (2011).
63. Thompson RB, Finlay WH. Using MRI to measure aerosol deposition. J. Aerosol Med. Pulm. Drug Deliv. 25(2), 55-62 (2012).
64. de Lange EE, Altes TA, Patrie JT et al. Evaluation of asthma with hyperpolarized helium-3 MRI: correlation with clinical severity and spirometry. Chest 130, 1055-1062 (2006). (Pubitemid 44583735)
65. Samee S, Altes T, Powers P et al. Imaging the lungs in asthmatic patients by using hyperpolarized helium-3 magnetic resonance: Assessment of response to methacholine and exercise challenge. J. Allergy Clin. Immunol. 111, 1205-1211 (2003). (Pubitemid 36683671)
66. Van Beek EJ, Dahmen AM, Stavngaard T et al. Hyperpolarised 3He MRI versus HRCT in COPD and normal volunteers: PHIL trial. Eur. Respir. J. 34, 1311-1321 (2009).
67. Jang YM, Oh YM, Seo JB et al. Quantitatively assessed dynamic contrast-enhanced magnetic resonance imaging in patients with chronic obstructive pulmonary disease: correlation of perfusion parameters with pulmonary function test and quantitative computed tomography. Invest. Radiol. 43, 403-410 (2008). (Pubitemid 351769898)
68. de Lange EE, Altes TA, Wright CM et al. Hyperpolarized gas MR imaging of the lung: safety assessment of inhaled helium-3. Proc. RSNA 89th Meeting Abstract 525 (2003).
69. Campana L, Kenyon J, Zhalehdoust-Sani S et al. Probing airway conditions governing ventilation defects in asthma via hyperpolarized MRI image functional modeling. J. Appl. Physiol. 106, 1293-1300 (2009).
70. Ruppert K, Mata JF, Brookeman JR, Hagspiel KD, Mugler JP. Exploring lung function with hyperpolarized (129)Xe nuclear magnetic resonance. Magn. Reson. Med. 51, 676-687 (2004). (Pubitemid 38420443)
71. Haage P, Adam G, Karaagac S et al. Mechanical delivery of aerosolized gadolinium-DTPA for pulmonary ventilation assessment in MR imaging. Invest. Radiol. 36, 240-243 (2001). (Pubitemid 32295627)
72. Haage P, Karaagac S, Spuntrup E, Truong HT, Schmidt T, Gunther RW. Feasibility of pulmonary ventilation visualization with aerosolized magnetic resonance contrast media. Invest Radiol. 40, 85-88 (2005). (Pubitemid 40144413)
73. Vartholomeos P, Mavroidis C, Hata N. Magnetic targeting of aggregated nanoparticles for advanced lung therapies: A robotics approach. Proc. IEEE RAS EMBS Int. Conf. Biomed. Robot. Biomechatron. 861-868 (2010).
74. Ally J, Martin B, Khamesee MB, Amirfazli WRA. Magnetic targeting of aerosol particles for cancer therapy. J. Magn. Magn. Mat. 293, 442-449 (2005). (Pubitemid 40608964)
75. Hanna N, Saltzman D, Mukai D et al. Two-dimensional and 3-dimensional optical coherence tomographic imaging of the airway, lung, and pleura. J. Thorac. Cardiovasc. Surg. 129(3), 615-622 (2005). (Pubitemid 40311322)
76. Coxson HO, Mayo J, Lam S, Santyr G, Parraga G, Sin DD. New and current clinical imaging techniques to study chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180(7), 588-597 (2009).
77. Newton RC, Kemp SV, Shah PL et al. Progress toward optical biopsy: bringing the microscope to the patient. Lung 18 9 (2), 111-119 (2011).
78. Thiberville L, Salaün M, Lachkar S et al. Confocal fuorescence endomicroscopy of the human airways. Proc. Am. Thorac. Soc. 6(5), 444-449 (2009).
79. Thiberville L, Moreno-Swirc S, Vercauteren T et al. In vivo imaging of the bronchial wall microstructure using fbered confocal fuorescence microscopy. Am. J. Respir. Crit. Care Med. 175(1), 22-31 (2007). (Pubitemid 46105305)
80. Thiberville L, Salaün M, Lachkar S et al. Human in vivo fuorescence microimaging of the alveolar ducts and sacs during bronchoscopy. Eur. Respir. J. 33(5), 974-985 (2009).
81. Usmani OS, Barnes PJ. Assessing and treating small airways disease in asthma and chronic obstructive pulmonary disease. Ann. Med. 44, 146-156 (2012).
82. King GG, Downie SR, Verbanck S et al. Effects of methacholine on small airway function measured by forced oscillation technique and multiple breath nitrogen washout in normal subjects. Respir. Physiol. Neurobiol. 148, 165-177 (2005). (Pubitemid 41132757)
83. King GG. Cutting edge technologies in respiratory research: lung function testing. Respirology 16(6), 883-890 (2011).
84. Aurora P, Kozlowska W, Stocks J. Gas mixing effciency from birth to adulthood measured by multiple-breath washout. Respir. Physiol. Neurobiol. 148, 125-139 (2005). (Pubitemid 41132754)
85. Downie SR, Salome CM, Verbanck S, Thompson B, Berend N, King GG. Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway infammation. Thorax 62, 684-689 (2007). (Pubitemid 47235010)
86. Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fbrosis. Eur. Respir. J. 22, 972-979 (2003). (Pubitemid 37540651)
87. Larsson A, Jonmarker C, Werner O. Ventilation inhomogeneity during controlled ventilation. Which index should be used? J. Appl. Physiol. 65, 2030-2039 (1988). (Pubitemid 19012305)
88. Amin R, Subbarao P, Jabar A et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 65, 379-383 (2010).
89. Horsley AR, Gustafsson PM, Macleod KW et al. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fbrosis. Thorax 63, 135-140 (2008). (Pubitemid 351236478)
90. Kraemer R, Blum A, Schibler A et al. Ventilation inhomogeneities in relation to standard lung function in patients with cystic fbrosis. Am. J. Respir. Crit. Care. Med. 171, 371-378 (2005). (Pubitemid 40223405)
91. Crawford AB, Makowska M, Paiva M, Engel LA. Convection-and diffusion-dependent ventilation maldistribution in normal subjects. J. Appl. Physiol. 59, 838-846 (1985). (Pubitemid 16214148)
92. Pavia M. Two new pulmonary functional indexes suggested by a simple mathematical model. Respiration 32, 389-403 (1975).
93. Verbanck S, Paiva M. Model simulations of gas mixing and ventilation distribution in the human lung. J. Appl. Physiol. 69, 2269-2279 (1990).
94. Verbanck S, Schuermans D, Van Muylem A et al. Ventilation distribution during histamine provocation. J. Appl. Physiol. 83, 1907-1916 (1997). (Pubitemid 28006490)
95. Verbanck S, Thompson BR, Schuermans D et al. Ventilation heterogeneity in the acinar and conductive zones of the normal ageing lung. Thorax 67(9), 789-795 (2012).
96. Verbanck S, Schuermans D, Paiva M, Vincken W. The functional beneft of anti-infammatory aerosols in the lung periphery. J. Allergy Clin. Immunol. 118(2), 340-346 (2006). (Pubitemid 44142721)
97. Verbanck S, Schuermans D, Meysman M et al. Noninvasive assessment of airway alterations in smokers: the small airways revisited. Am. J. Respir. Crit. Care Med. 170, 414-419 (2004). (Pubitemid 39214616)
98. Thompson BR, Verbanck S, King GG et al. Novel measurements of acinar ventilation after lung transplant. Am. J. Respir. Crit. Care Med. 179, A2099 (2009).
99. Verbanck S, Thompson BR, Schuermans D et al. Ventilation heterogeneity in the acinar and conductive zones of the normal ageing lung. Thorax 67(9), 789-795 (2012).
100. Beydon N, Davis SD, Lombardi E et al. An offcial American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am. J. Respir. Crit. Care Med. 175, 1304-1345 (2007). (Pubitemid 46905757)
101. DuBois A, Brody A, Lewis D et al. Oscillation mechanics of lungs and chest in man. J. Appl. Physiol. 8, 587-594 (1956).
102. Goldman MD, Saadeh C, Ross D. Clinical applications of forced oscillation to assess peripheral airway function. Respir. Physiol. Neurobiol. 148, 179-194 (2005). (Pubitemid 41135872)
103. King GG, Downie SR, Verbanck S et al. Effects of methacholine on small airway function measured by forced oscillation technique and multiple breath nitrogen washout in normal subjects. Respir. Physiol. Neurobiol. 148, 165-177 (2005). (Pubitemid 41132757)
104. Goldman M. Clinical application of forced oscillation. Pulm. Pharmacol. Therap. 14, 341-350 (2001). (Pubitemid 32977017)
105. Van Noord JA, Smeets J, Clément J, Van de Woestijne KP, Demedts M. Assessment of reversibility of airfow obstruction. Am. J. Respir. Crit. Care Med. 150, 551-554 (1994).
106. Shi Y, Aledia AS, Tatavoosian AV, Vijayalakshmi S, Galant, SP, George SC. Relating small airways to asthma control by using impulse oscillometry in children. J. Allergy Clin. Immunol. 129(3), 671-678 (2012).
107. Delacourt C, Lorino H, Herve-Guillot M, Reinert P, Harf A, Housset B. Use of the forced oscillation technique to assess airway obstruction and reversibility in children. Am. J. Respir. Crit. Care Med. 161, 730-736 (2000). (Pubitemid 30171724)
108. Nielsen K, Bisgaard H. Discriminative capacity of bronchodilator response measured with three different lung function techniques in asthmatic and healthy children aged 2 to 5 years. Am. J. Respir. Crit. Care Med. 164, 554-559 (2001). (Pubitemid 32801655)
109. Dellacà RL, Gobbi A, Pastena M et al. Home monitoring of within-breath respiratory mechanics by a simple and automatic forced oscillation technique device. Physiol. Meas. 31(4), N11 (2010).
110. Oostveen E, MacLeod D, Lorino H et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. Eur. Respir. J. 22, 1026-1041 (2003). (Pubitemid 37540659)
111. Barnes PJ, Dweik RA, Gelb AF et al. Exhaled nitric oxide in pulmonary diseases: A comprehensive review. Chest 138(3), 682-692 (2010).
112. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J. Appl. Physiol. 85, 653-666 (1998). (Pubitemid 28365835)
113. Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 53, 91-95 (1998). (Pubitemid 28212132)
114. Menzies D, Nair A, Hopkinson P, McFarlane L, Lipworth BJ. Differential anti-infammatory effects of large and small particle size inhaled corticosteroids in asthma. Allergy 62(6), 661-667 (2007). (Pubitemid 46763441)
115. Cohen J, Postma DS, Douma WR, Vonk JM, De Boer AH, ten Hacken NHT. Particle size matters: diagnostics and treatment of small airways involvement in asthma. Eur. Respir. J. 37, 532-540 (2011).
116. Verbanck S, Schuermans D, Vincken W. Infammation and airway function in the lung periphery of patients with stable asthma. J. Allergy Clin. Immunol. 125(3), 611-616 (2010).
117. Van Veen IH, Sterk PJ, Schot R, Gauw SA, Rabe KF, Bel EH. Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. Eur. Respir. J. 27(5), 951-956 (2006). (Pubitemid 44911108)
118. Shaw DE, Berry MA, Thomas M et al. The use of exhaled nitric oxide to guide asthma management: A randomized controlled trial. Am. J. Respir. Crit. Care Med. 176(3), 231-237 (2007). (Pubitemid 47195872)
119. Stick S, Franklin P. NO more dogma. Nitric oxide marker in asthma. Am. J. Respir. Crit. Care Med. 179(2), 87-88 (2009).
120. Taylor DR. Exhaled nitric oxide: still alive, not laid to rest. Am. J. Respir. Crit. Care. Med. 179, 88-89 (2009).